China NMPA approves subcutaneous lecanemab for early Alzheimer’s
Eisai and Biogen said China’s NMPA approved a lecanemab subcutaneous formulation for initiation treatment in early Alzheimer’s, using a subcutaneous autoinjector (SC-AI).
, Ltd. and Biogen Inc. (Nasdaq: BIIB) said the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation, described as a subcutaneous autoinjector (SC-AI), of the anti-amyloid beta (AB) proto…